[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509658":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":132,"centralContacts":11,"locations":137,"responsibleParty":162,"collaborators":11,"id":165,"slug":166,"hasResults":167,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":11,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":173,"minAge":11,"maxAge":11,"enrollmentInfo":174,"targetDuration":11,"studyType":177,"phases":178,"briefSummary":180,"conditions":181,"keywords":11,"overallStatus":140,"whyStopped":11,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy volonteer","EXPERIMENTAL",null,[13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34],"Biological: Blood and urine samples","Genetic: Blood samples","Other: Cardiovascular assessment","Behavioral: Dietary intake","Other: Anthropometric parameters","Other: Hemodynamic parameters","Behavioral: Assessment of compliance with antihypertensive treatments for treated participants","Other: Ambulatory 24 hours measurment of blood pressure","Biological: 24 hours urinary collection","Other: General questionnaires","Other: Women specific questionnaire","Behavioral: Women specific questionnaire","Diagnostic Test: NYHA dyspnea questionnaire","Behavioral: Anxiety questionnaire","Behavioral: Epworth Sleepiness Scale","Other: A questionnaire on the \"perception of the management of cardiovascular risk factors\"","Behavioral: A questionnaire on eating behaviors","Behavioral: A questionnaire on eating habits to determine consumer profiles","Dietary Supplement: A questionnaire on food supplements use","Other: SARS-CoV-2 Infection Questionnaire","Other: Instantaneous expired air analysis","Biological: Capillary sampling",[36,40,44,48,53,57,61,64,67,70,74,78,82,86,89,91,96,100,104,108,112,116,121,124,128],{"type":37,"name":38,"description":38,"armGroupLabels":39,"otherNames":11},"BIOLOGICAL","Blood and urine samples",[9],{"type":41,"name":42,"description":42,"armGroupLabels":43,"otherNames":11},"GENETIC","Blood samples",[9],{"type":6,"name":45,"description":46,"armGroupLabels":47,"otherNames":11},"Cardiovascular assessment","Echocardiography, Lung ultrasound, pulse wave velocity, carotid stiffness and thickness, Central and peripheral blood pressure, carotid pulse pressure, abdominal aorta ultrasound, jugular vein ultrasound, liver elastography (Optional).",[9],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":11},"BEHAVIORAL","Dietary intake","Food frequency questionnaires, ''Dutch eating behaviour questionnaire'' and dietary supplement questionnaire",[9],{"type":6,"name":54,"description":55,"armGroupLabels":56,"otherNames":11},"Anthropometric parameters","Measurement of height, weight, abdominal circumference, hip circumference, arm circumference",[9],{"type":6,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"Hemodynamic parameters","Systolic pressure index measurement",[9],{"type":6,"name":58,"description":62,"armGroupLabels":63,"otherNames":11},"Heart rate measurements, blood pressure measurements, orthostatic BP measurements",[9],{"type":6,"name":58,"description":65,"armGroupLabels":66,"otherNames":11},"Blood pressure measurements by \"unattended BP\" monitor over 5 min",[9],{"type":6,"name":58,"description":68,"armGroupLabels":69,"otherNames":11},"Electrocardiogram",[9],{"type":49,"name":71,"description":72,"armGroupLabels":73,"otherNames":11},"Assessment of compliance with antihypertensive treatments for treated participants","EVALOBS scale and compliance questionnaire",[9],{"type":6,"name":75,"description":76,"armGroupLabels":77,"otherNames":11},"Ambulatory 24 hours measurment of blood pressure","For the first 100 patients willing to participate",[9],{"type":37,"name":79,"description":80,"armGroupLabels":81,"otherNames":11},"24 hours urinary collection","For the first 100 patients willing to participate. For biobank constitution and measurement of microalbuminuria, creatininuria, osmolarity, natriuresis, kaliuresis, urea, proteinuria and urine dipstick",[9],{"type":6,"name":83,"description":84,"armGroupLabels":85,"otherNames":11},"General questionnaires","Collection of socio-demographic data such as age, level of education, profession, household income, smoking status, physical activity, perception of health, prematurity, height and weight at birth, family and personal history especially cardiovascular (history of stroke, myocardial infarction, heart failure, current pathologies, drugs, tobacco...)",[9],{"type":6,"name":87,"description":87,"armGroupLabels":88,"otherNames":11},"Women specific questionnaire",[9],{"type":49,"name":87,"description":87,"armGroupLabels":90,"otherNames":11},[9],{"type":92,"name":93,"description":94,"armGroupLabels":95,"otherNames":11},"DIAGNOSTIC_TEST","NYHA dyspnea questionnaire","Determination of NYHA class.",[9],{"type":49,"name":97,"description":98,"armGroupLabels":99,"otherNames":11},"Anxiety questionnaire","Assessment of anxiety",[9],{"type":49,"name":101,"description":102,"armGroupLabels":103,"otherNames":11},"Epworth Sleepiness Scale","sleep quality assessment",[9],{"type":6,"name":105,"description":106,"armGroupLabels":107,"otherNames":11},"A questionnaire on the \"perception of the management of cardiovascular risk factors\"","Patient's evaluation of cardiovascular risk factors by the health system",[9],{"type":49,"name":109,"description":110,"armGroupLabels":111,"otherNames":11},"A questionnaire on eating behaviors","Assessment of eating behaviors",[9],{"type":49,"name":113,"description":114,"armGroupLabels":115,"otherNames":11},"A questionnaire on eating habits to determine consumer profiles","Assessement of eating habit to create a consumer profile",[9],{"type":117,"name":118,"description":119,"armGroupLabels":120,"otherNames":11},"DIETARY_SUPPLEMENT","A questionnaire on food supplements use","Evaluation od food supplements intake",[9],{"type":6,"name":122,"description":122,"armGroupLabels":123,"otherNames":11},"SARS-CoV-2 Infection Questionnaire",[9],{"type":6,"name":125,"description":126,"armGroupLabels":127,"otherNames":11},"Instantaneous expired air analysis","Carbon monoxyde analysis in expired air",[9],{"type":37,"name":129,"description":130,"armGroupLabels":131,"otherNames":11},"Capillary sampling","Capillary sampling for pollutant analysis (Optional)",[9],[133],{"name":134,"affiliation":135,"role":136},"Nicolas Girerd, MD, PhD","Centre d'Investigation Clinique 1433 module Plurithématique - CHRU Nancy","PRINCIPAL_INVESTIGATOR",[138],{"facility":139,"status":140,"city":141,"state":142,"zip":143,"country":144,"countryCode":145,"cosmosGeoPoint":146,"geoPoint":151,"contacts":152},"CHRU de Nancy","RECRUITING","Vandœuvre-lès-Nancy","Lorraine","54500","France","FR",{"type":147,"coordinates":148},"Point",[149,150],6.17114,48.66115,{"lat":150,"lon":149},[153,157,159],{"name":134,"role":154,"phone":155,"phoneExt":11,"email":156},"CONTACT","+333 83 15 73 22","n.girerd@chru-nancy.fr",{"name":158,"role":136,"phone":11,"phoneExt":11,"email":11},"Nicolas GIRERD, MD, PhD",{"name":160,"role":161,"phone":11,"phoneExt":11,"email":11},"Jean Marc BOIVIN, MD, PhD","SUB_INVESTIGATOR",{"type":136,"investigatorFullName":163,"investigatorTitle":164,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Pr. Nicolas GIRERD","Coordinating doctor","100509658","family-inheritance-gene-gene-and-gene-environment-interactions-in-the-field-of-cardiovascular-and-renal-diseases-fifth-visit-of-the-stanislas-cohort-100509658",false,"NCT05916287","FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort","HÉRITABILITÉ FAMILIALE, INTERACTIONS GÈNE-GÈNE ET GÈNE-ENVIRONNEMENT DANS LE DOMAINE DES MALADIES CARDIOVASCULAIRES ET RENALES. Cinquième Visite de la Cohorte STANISLAS","Inclusion Criteria:\n\n* aged over 18\n* Person who participated in the Stanislas Cohort\n* Person affiliated to a social security scheme or beneficiary of such a scheme\n* Person having received complete information on the organization of the research and having signed an informed consent\n\nExclusion Criteria:\n\n* Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code:\n\n  * Pregnant woman, parturient or nursing mother\n  * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * Person of full age unable to express consent",true,"ALL",{"count":175,"type":176},3000,"ESTIMATED","INTERVENTIONAL",[179],"NA","The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.",[182,183,184,185,186],"Cardiovascular Diseases","Cohort Studies","Genotype","Risk Factors","Nutrition","2023-08-11",{"date":189,"type":190},"2023-08-15","ACTUAL",{"date":192,"type":190},"2023-07-13",{"date":194,"type":176},"2027-07-13",{"name":5,"class":6},1]